ThromboGenics NV (EBR: THR) announced on Wednesday its intention to change its name to Oxurion NV.
The name Oxurion is derived from a combination of 'oxygen' and 'Orion'. Increasing oxygen levels plays a key role in helping to prevent and reverse several of the key underlying factors leading to diabetic eye disease. Oxygen, therefore, references the company's mission to target the onset of these diseases.
Orion was a Greek mythical figure who, after being blinded, had his vision restored by the God of the Sun, Helios. Again, this is a reference to the company's mission to focus on enhancing vision and fighting blindness through its research and drug treatments.
The company has issued a convening notice seeking the approval of its shareholders for the name change at an extraordinary general meeting (EGM), set to take place on Friday 27 July.
Subject to shareholder approval, the name change will come into effect in the week commencing 10 September. The name change will also result in the company's stock ticker symbol changing from 'THR' to 'OXUR'.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes